Figure 4.

Ninj2 shRNA or KO inhibits human glioma cell migration and invasion. A172 glioma cells (A and B), U251MG glioma cells (C and D) or the primary human glioma cells (derived two patients, “P1/P2”, C and D) were transduced with lentiviral Ninj2 shRNAs (“sh-Ninj2”, two different sequences “Seq1/Seq2”), control shRNA (“sh-C”) or the CRISPR/Cas9 Ninj2 KO construct (“ko-Ninj2”), stable cells were established via puromycin selection; Cells were subjected to Transwell assays (A and C) and Matrigel Transwell assays (B and D) (both for 24h), results were quantified. For each condition, at least 1000 cells in five random views (magnification : 1×200) were included to calculate the average number of migrated/invasive cells. For each assay, n=5. *p<0.05 vs. “Pare” cells. Experiments in this figure were repeated four times, and similar results were obtained.